Black checkmark with a sparkle and a curved line underneath on a white background.
Company

USANA HEALTH SCIENCES INC

Ticker
USNA
Sector
Industry
Report date
November 12, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include USANA's Q3 2026 earnings call reporting a narrowed loss and a 4% sales decline, alongside a lowered fiscal 2026 outlook. The company expanded collegiate athlete partnerships with the University of Utah and reported a net loss of $5.6 million for Q3 2026.

Recent developments:
  • USANA reported a net loss of $5.6 million for Q3 2026, with sales declining 4% and a narrowed loss compared to prior periods [N5][N4][N6].
  • The company lowered its fiscal 2026 outlook following Q3 results [N4][N5].
  • USANA held $178.9 million in cash and cash equivalents as of October 3, 2026, maintaining a current ratio of 2.59 [S2].
  • The company expanded collegiate athlete partnerships with the University of Utah in October 2026 [N8].
  • Q3 2026 earnings call and transcript provided detailed operational and financial insights [N1][N2][N3].
Overview

USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products globally. The company operates primarily through three segments: Core Nutritional, Hiya, and Rise. Core Nutritional accounts for the majority of sales and is organized geographically into Asia Pacific and Americas and Europe regions. Hiya and Rise focus on children's health and wellness products and have expanded their geographic reach since acquisition. USANA distributes products via direct selling, direct-to-consumer, third-party marketplaces, and retail channels. The company faces regulatory scrutiny related to direct selling practices, especially in the United States and China, and manages risks associated with Brand Partner compliance and compensation plans. Financially, USANA reported a net loss in recent quarters with declining sales and maintains liquidity with a strong current ratio. The company continues to invest in partnerships and product offerings while navigating regulatory and market challenges.

Executive summary

USANA Health Sciences, Inc. is a global nutritional and personal care products company operating through Core Nutritional, Hiya, and Rise segments. The company reported a net loss of $5.6 million for Q3 2026 with sales declining 4%, and lowered its fiscal 2026 outlook. As of October 3, 2026, USANA held $178.9 million in cash and equivalents with a current ratio of 2.59. The business model includes direct selling and omni-channel distribution, with regulatory risks related to direct selling practices and international operations, especially in China. Recent developments include expanded collegiate athlete partnerships and ongoing adjustments to the Brand Partner Compensation Plan [S2][N1][N4][N5][N8]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for USNA

Bull case model:

USANA's diversified distribution channels and geographic presence provide multiple avenues for customer engagement and revenue generation. The company's focus on science-based nutritional products aligns with consumer health trends. Recent expansions, such as collegiate athlete partnerships and the integration of Hiya and Rise segments, support broader market penetration. The company's liquidity position and cash flow from operations indicate operational resilience. Adjustments to the Brand Partner Compensation Plan aim to enhance incentives and sales growth potential.

Bear case model:

USANA faces significant regulatory risks related to direct selling practices, including potential FTC actions and evolving laws affecting Brand Partner classification and compensation. Sales declines and net losses in recent quarters highlight operational challenges. The company's reliance on Brand Partners exposes it to risks of non-compliance and adverse publicity. Economic conditions, competition from larger players, and supply chain disruptions may further pressure financial performance. The lowered fiscal 2026 outlook reflects uncertainties in market demand and execution risks.

Moat:

USANA's moat is supported by its established direct selling network and diversified omni-channel distribution platform, including direct-to-consumer and retail channels. The company's science-based product portfolio and geographic diversification, particularly in Asia Pacific and Americas, contribute to its competitive positioning. However, the business model is subject to regulatory scrutiny and compliance risks inherent in direct selling, which may limit operational flexibility. Brand Partner relationships and compensation plans are critical to maintaining sales momentum and market presence. The company's acquisitions of Hiya and Rise expand its product offerings and customer base, enhancing its market reach.

Risks overview
Risks summary
Regulatory and legal risks related to direct selling practices and Brand Partner management represent the most significant risks to USANA's business and financial condition.
Risks details:

• Regulatory and Legal Risks Related to Direct Selling: USANA is subject to intense government scrutiny and evolving regulations in the direct selling industry, including FTC enforcement actions and potential restrictions on compensation plans and marketing practices. Non-compliance by Brand Partners with marketing and advertising laws could lead to legal actions and increased regulatory oversight.
• Risks Related to China Operations: The Greater China region is significant for USANA's business and growth. Operations are subject to stringent government regulation and require approvals for expansion. Changes in laws or enforcement could materially harm the company's consolidated results.
• Brand Partner Classification and Compensation Risks: Legal and regulatory changes could affect the classification of Brand Partners as independent contractors, potentially imposing employer obligations on USANA. Changes to the Brand Partner Compensation Plan may be viewed negatively and could impact the company's ability to attract and retain partners.
• Operational and Supply Chain Risks: USANA's manufacturing and supply chain are subject to risks including raw material availability, regulatory compliance, and potential product liability. Disruptions could adversely affect results of operations.
• Financial Performance and Market Risks: Recent net losses and sales declines, along with a lowered fiscal outlook, indicate operational challenges. Economic conditions, competition, and adverse publicity may impact financial results and stock market performance.

FINAL FORECAST FOR USNA

Final take one line
USANA Health Sciences exhibits very high information visibility with detailed financial disclosures, regulatory risk factors, and recent operational updates.
Final take 12 to 24 month view

Business trends: USANA's business shows ongoing challenges with sales declines and net losses, alongside strategic expansions in partnerships and product segments.
Execution milestones: Integration of Hiya and Rise segments, updates to Brand Partner Compensation Plan, and expanded athlete partnerships.
Key risks: Regulatory scrutiny of direct selling practices, Brand Partner compliance and classification risks, and operational challenges in international markets, especially China.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • USANA Health Sciences, Inc. is a global nutritional, personal health and wellness company that develops and manufactures science-based nutritional and personal care products.
  • The company operates through three reportable segments: Core Nutritional, Hiya, and Rise.
  • Core Nutritional is the primary business, accounting for approximately 83% of consolidated net sales year-to-date 2026, organized into Asia Pacific (Greater China, Southeast Asia Pacific, North Asia) and Americas and Europe regions.
  • Hiya Health Products, LLC is a direct-to-consumer provider of children's health and wellness products, acquired in 2024 with a controlling interest of 78.85%, operating in the US, Canada, and UK.
  • Rise Wellness, Inc. was acquired in 2022 and expanded product offerings and distribution in the US and Canada.
  • The company sells products through an omni-channel platform including direct selling, direct-to-consumer, third-party marketplaces, and retail channels.
  • As of October 3, 2026, USANA had cash and cash equivalents of $178.9 million, current assets of $290.2 million, and current liabilities of $112.3 million, resulting in a current ratio of 2.59 and a cash ratio of 1.59.
  • For the three months ended October 3, 2026, USANA reported net sales of $205.9 million and a net loss of $5.6 million, with basic and diluted EPS of -$0.30.
  • For the nine months ended October 3, 2026, net sales were $679.4 million with a net loss of $19.4 million.
  • Brand Partner incentives are a significant operating expense, totaling $71.9 million for Q3 2026 and $244.0 million for the nine months ended October 3, 2026.
  • The company has goodwill and intangible assets on its balance sheet, with goodwill impairment noted in prior periods but none in the latest quarter.
  • USANA faces regulatory risks related to direct selling, including scrutiny by the FTC and compliance with marketing and compensation plan laws.
  • The company is subject to risks related to its China business, including government regulation and the need for approvals for expansion.
  • USANA's Brand Partners are independent contractors, but legal and regulatory changes could affect their classification and related obligations.
  • The company has recently updated its Brand Partner Compensation Plan and launched an Affiliate program in certain markets.
  • USANA reported a net loss of $5.6 million for Q3 2026 and narrowed its loss compared to prior periods, with sales declining 4%.
  • The company lowered its fiscal 2026 outlook as reported in November 2026.
  • USANA expanded collegiate athlete partnerships with the University of Utah in October 2026.
  • The company reported equity-based compensation expenses of approximately $10.3 million for the nine months ended October 3, 2026.
  • USANA's operations are subject to risks including product liability, supply chain disruptions, and extensive government regulation of products and manufacturing.
  • The company reported net cash provided by operating activities of $45.0 million for the nine months ended October 3, 2026, with investing activities using $10.2 million and financing activities using $17.8 million.
  • USANA's stockholders' equity attributable to the company was $526.8 million as of October 3, 2026.
  • The company faces risks from economic conditions, competition, intellectual property, public health crises, and stock market factors.
  • USANA's recent news includes detailed Q3 2026 earnings call highlights and transcripts, reporting narrowing losses and sales declines, and updates to fiscal outlook [N1][N2][N3][N4][N5][N6][N7].
  • The company expanded collegiate athlete partnerships with Utah in October 2026 [N8].
Sources
Sources - Context summary

Generated 2026-11-12

Sources - Earning calls
  • N1
  • N2
  • N3
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-16 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-07 | www.nasdaq.com | USANA Health Sciences Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/usana-health-sciences-q3-earnings-call-highlights
  • N2 | 2026-11-04 | www.nasdaq.com | USANA (USNA) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/usana-usna-q3-2026-earnings-call-transcript
  • N3 | 2026-11-04 | www.nasdaq.com | USANA Health Sciences Q3 26 Earnings Conference Call At 11:00 AM ET | https://www.nasdaq.com/articles/usana-health-sciences-q3-26-earnings-conference-call-11-00-am-et
  • N4 | 2026-11-04 | www.nasdaq.com | USANA's Q3 Loss Narrows, Sales Decline 4%; FY26 Outlook Lowered | https://www.nasdaq.com/articles/usanas-q3-loss-narrows-sales-decline-4-fy26-outlook-lowered
  • N5 | 2026-11-04 | www.nasdaq.com | USANA Health Sciences, Inc. Reports Q3 2026 Net Loss of $(5.6) million and Updates Fiscal 2026 Outlook | https://www.nasdaq.com/articles/usana-health-sciences-inc-reports-q3-2026-net-loss-56-million-and-updates-fiscal-2026
  • N6 | 2026-11-04 | www.nasdaq.com | USANA Health Sciences Q3 Loss Decreases | https://www.nasdaq.com/articles/usana-health-sciences-q3-loss-decreases
  • N7 | 2026-11-03 | www.nasdaq.com | USANA Health Sciences (USNA) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/usana-health-sciences-usna-reports-q3-loss-lags-revenue-estimates
  • N8 | 2026-10-07 | www.nasdaq.com | USANA Health Sciences Expands Collegiate Athlete Partnerships With Utah | https://www.nasdaq.com/articles/usana-health-sciences-expands-collegiate-athlete-partnerships-utah
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine